𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia

✍ Scribed by MARI MURASHITA; TAKESHI INOUE; ICHIRO KUSUMI; SHIN NAKAGAWA; KOUICHI ITOH; TERUAKI TANAKA; TAKESHI IZUMI; HIROSHI HOSODA; KENJI KANGAWA; TSUKASA KOYAMA

Book ID
108962081
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
57 KB
Volume
61
Category
Article
ISSN
1323-1316

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term treatment with long-acting ris
Long-term treatment with long-acting risperidone in Korean patients with schizophrenia
✍ Moon-Soo Lee; Young-Hoon Ko; Sang-Hoon Lee; Yong-Jin Seo; Seung-Hyun Kim; Sook-H 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract ## Objectives We evaluated the efficacy and safety of long‐acting risperidone for 48‐week period in Korean patients. ## Methods This was a non‐randomized, open‐label, single‐centered, 48‐week study. Each of the participants visited the hospital every 2 weeks, and injections were give

Efficacy and safety of long-acting rispe
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder
✍ Robert A. Lasser; Cynthia A. Bossie; Young Zhu; Georges Gharabawi; Mariëlle Eerd 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

## Abstract ## Background Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long‐acting risperidone, the first long‐acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery. ## Objective To assess the effi

Long-term safety and efficacy of long-ac
Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients
✍ Werner Kissling; Per Glue; Rossella Medori; Steve Simpson 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 1 views

## Abstract This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot a